ARTICLE | Clinical News

SMART Anti-gamma interferon antibody: Phase I

November 6, 2000 8:00 AM UTC

In a dose-escalating Phase I trial in 22 healthy volunteers, single intravenous doses of 0.01 mg/kg to 4.0 mg/kg of the antibody were safe, with no serious or severe adverse events reported. The half-life of the antibody was 2-3 weeks, PDLI said. In addition doses ?0.03 mg/kg gave a ?60 percent reduction in delayed-type hypersensitivity (DTH) responses compared to that observed in a pre-treatment antigen challenge in 22 of 29 evaluable skin tests, and a ?0 percent reduction in half of the 29 tests. Data were presented at the American College of Rheumatology meeting in Philadelphia. ...